NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Windlas Biotech Q2 FY27 Revenue Up 18.7% YoY to ₹263.9 Cr, Net Profit Flat at ₹18.05 Cr
Windlas Biotech reported a 18.7% YoY increase in revenue from operations to ₹263.91 Cr for the quarter ended September 30, 2026, compared to ₹222.40 Cr in the year-ago quarter. Net profit remained largely flat at ₹18.05 Cr (vs ₹17.80 Cr in Q2 FY26) due to higher raw material and employee benefit expenses. Concurrently, founder Ashok Kumar Windlass stepped down as Whole-time Director to become Founder President (Senior Management Personnel) at an annual remuneration of ₹1.56 Cr, while Managing Director Hitesh Windlass was appointed Chairman of the Board.
உச்சம் நம்பிக்கை
என்ன மாறியதுWindlas Biotech reported Q2 FY27 financial results and executed a leadership transition elevating MD Hitesh Windlass to Board Chairman while founder Ashok Kumar Windlass moved to a Senior Management role.
ஏன் இது முக்கியம்Topline growth remains healthy near the 18-20% guidance band, but margin pressure kept bottom-line growth flat YoY; the leadership succession formalizes next-generation governance.
📅 குறுகிய காலம்Market reaction may be muted given that healthy topline expansion was offset by flattish net profit growth.
📈 நீண்ட காலம்Execution on margin improvement, injectables scale-up, and exports expansion remain the key drivers for structural growth.
⚠ அபாய எச்சரிக்கைகள்
Margin compression driven by higher input costs and personnel expenses
Related-party transaction requiring shareholder approval under Section 188(1)(f) for office of profit
👀 கவனிக்க வேண்டியவை
Track whether margin compression eases in the upcoming quarters as the new injectable facility ramps up and whether shareholder approval for related-party appointment of the Founder President is obtained.
Q2 FY27 Revenue Up 19% YoY to ₹264 Cr; Plant-6 Commercialized and EU GMP Received
Windlas Biotech reported a 19% YoY increase in Q2 FY27 revenue from operations to ₹264 crore, marking its 15th consecutive quarter of record revenue. Adjusted EBITDA for Q2 FY27 rose 20% YoY to ₹36 crore (margin 13.7%), while reported PAT stood at ₹18 crore after accounting for ₹7 crore of non-cash ESOP charges. The core CDMO segment led performance with 34% YoY growth to ₹215 crore (82% of revenue), offsetting a 30% drop in Trade Generics. Operationally, Plant-6 was commercialized in September 2026, and Plant-4 and Plant-5 received EU GMP certifications.
உச்சம் நம்பிக்கை
என்ன மாறியதுWindlas commercialized Plant-6 in September 2026 and secured EU GMP approval for Plants 4 & 5, alongside reporting 19% YoY revenue growth for Q2 FY27.
ஏன் இது முக்கியம்The core CDMO business is expanding strongly at 34% YoY, and international regulatory clearances (EU GMP) alongside new capacity (Plant-6) position the company for sustained export and injectables growth.
📅 குறுகிய காலம்Solid operational results and operationalization of Plant-6 indicate healthy underlying demand, though non-cash ESOP charges will continue to cause a variance between adjusted and reported profit figures.
📈 நீண்ட காலம்EU GMP certifications for Plant-4 and Plant-5 (injectables) plus the commissioning of Plant-6 support the strategic transition into higher-margin regulated export markets.
⚠ அபாய எச்சரிக்கைகள்
Trade Generics & Institutional revenue contracted 30% YoY in Q2 due to portfolio restructuring (shifting away from codeine-based products)
High client concentration in the contract manufacturing (CDMO) vertical
Drag of non-cash ESOP expenses on reported margins
👀 கவனிக்க வேண்டியவை
Track the revenue ramp-up and margin contribution from the newly commercialized Plant-6 and the timeline of commercial supplies post-EU GMP approval for Plant-4 and Plant-5.
Windlas Biotech: Chairman Vivek Dhariwal Resigns; Two Independent Directors Appointed for 5 Years
Windlas Biotech announced that Independent Director and Chairman of the Board, Mr. Vivek Dhariwal, has resigned effective October 12, 2026, citing personal reasons and prior commitments with no other material reasons stated. To reconstitute the board, the company appointed Mr. Aashish Mehra and Mr. Soni Saran Singh as Additional Independent Directors, both for a 5-year tenure subject to shareholder approval. Mr. Mehra brings over two decades of strategy experience in life sciences, while Mr. Singh brings over three decades of manufacturing leadership. The board overhaul comes as the company operates at a trailing-twelve-month revenue of Rs 942 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard Chairman Vivek Dhariwal resigned, and two new Independent Directors (Aashish Mehra and Soni Saran Singh) were appointed to the board on October 12, 2026.
ஏன் இது முக்கியம்While operational leadership remains intact, the departure of the Board Chairman triggers governance changes and committee realignments (NRC and CSR).
Effective date of changes: அக்டோபர் 12, 2026Appointment tenure (both directors): 5 consecutive yearsTTM Revenue context: Rs 942 கோடி
📅 குறுகிய காலம்Neutral market impact expected as daily CDMO operations and executive management are unaffected by these independent board shifts.
📈 நீண்ட காலம்Limited operational impact; new independent directors add experience in life sciences strategy and electronics/technology manufacturing.
⚠ அபாய எச்சரிக்கைகள்
Vacancy created in the Chairman role requiring new board leadership selection
👀 கவனிக்க வேண்டியவை
Track the upcoming appointment of a new Board Chairman and monitor the voting outcome on the director appointments in the subsequent general meeting or postal ballot.
18% YoY Revenue Growth to Rs 248 Cr in Q1 FY27; Plant 6 Commercialization by H1
Windlas Biotech reported its highest-ever quarterly revenue of Rs 248 crore in Q1 FY27, marking 14 consecutive quarters of growth. The CDMO segment was the primary driver, growing 29% YoY to Rs 207 crore, while the Trade Generics segment (Rs 30 crore) was impacted by the discontinuation of codeine-based products. Adjusted PAT (excluding Rs 7.2 crore non-cash ESOP expenses) grew 37% YoY to Rs 25 crore. The company is on track to commercialize Plant 6 by the end of H1 FY27, which is expected to add approximately Rs 3 crore in quarterly depreciation starting Q3.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company achieved record quarterly revenue and provided a firm timeline for the commercialization of its next major capacity expansion (Plant 6).
ஏன் இது முக்கியம்The strong performance in CDMO and Exports offsets the regulatory impact on the Trade Generics business, proving the resilience of the diversified business model and setting the stage for further scale via Plant 6.
📅 குறுகிய காலம்The stock may react positively to the record revenue and the 37% growth in adjusted PAT, alongside the clarity on the buyback completion.
📈 நீண்ட காலம்The structural shift toward injectables and the expansion of the export vertical provide a pathway for sustained 18-20% growth as Plant 6 ramps up.
⚠ அபாய எச்சரிக்கைகள்
High client concentration in the CDMO segment
Volatility in API prices impacting margins
Regulatory risks associated with product portfolio changes
👀 கவனிக்க வேண்டியவை
Watch for the successful commissioning of Plant 6 by September 2026 and its subsequent impact on margins as depreciation kicks in. Monitor the recovery in the Trade Generics segment as the company launches new products to replace the discontinued codeine portfolio.
18% Revenue Growth to ₹248 Cr in Q1 FY27; CDMO Vertical Surges 29% YoY
Windlas Biotech reported its 14th consecutive quarter of record revenue at ₹248 Cr for Q1 FY27, driven by a robust 29% growth in its core CDMO segment. Adjusted PAT (excluding non-cash ESOP expenses) grew 37% YoY to ₹25 Cr, though reported PAT stood at ₹18 Cr due to a ₹7.16 Cr ESOP charge. The company completed a ₹47 Cr share buyback and is on track to commercialize its new Plant-6 in H1 FY27. While the Trade Generics segment declined 32% due to product portfolio shifts, the Exports vertical showed strong momentum with 79% growth.
உச்சம் நம்பிக்கை
என்ன மாறியதுWindlas achieved its highest-ever quarterly revenue while successfully navigating the discontinuation of codeine-based products in its Trade Generics segment.
ஏன் இது முக்கியம்The strong performance in the CDMO vertical (84% of revenue) and the upcoming capacity expansion at Plant-6 indicate a solid growth trajectory and operational leverage despite industry-wide volume pressures.
Q1 FY27 Revenue: ₹248 கோடிCDMO Revenue Growth: 29% YoYAdjusted PAT: ₹25 கோடிNon-cash ESOP Expense: ₹7.16 கோடிBuyback vs Market Cap: ~2.37%Q1 வருவாய் vs TTM வருவாய்: ~27.4%
📅 குறுகிய காலம்The market is likely to react positively to the record revenue and strong CDMO growth, though the reported PAT impact from ESOPs may be a minor talking point.
📈 நீண்ட காலம்The structural shift toward higher-margin injectables and the commercialization of new facilities (Plant-6) support the company's long-term growth target of 18-20%.
⚠ அபாய எச்சரிக்கைகள்
32% decline in Trade Generics & Institutional vertical
High client concentration in the CDMO segment
Impact of non-cash ESOP expenses on reported profitability
👀 கவனிக்க வேண்டியவை
Watch for the successful commercialization of Plant-6 in H1 FY27 and the ramp-up of the new injectables facility, which are key to sustaining the 18-20% growth guidance.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
₹6.30 Final Dividend: Windlas Biotech Sets July 16 as Record Date for 25th AGM
Windlas Biotech has scheduled its 25th Annual General Meeting (AGM) for July 23, 2026, and fixed July 16, 2026, as the record date for a final dividend of ₹6.30 per share. This dividend represents a 126% payout on the face value of ₹5 and approximately 19.9% of the TTM EPS of ₹31.61. The company is also seeking shareholder approval for the re-appointment of Managing Director Hitesh Windlass and the appointment of Dr. Tarashree Singhal as an Independent Director for a five-year term. Financially, the company remains stable with a low debt-to-equity ratio of 0.06 and TTM revenue of ₹904 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the schedule for its 25th AGM and confirmed the record date for its ₹6.30 final dividend.
ஏன் இது முக்கியம்The announcement confirms a cash return to shareholders (approx. 0.73% yield at current price) and ensures governance continuity through director appointments.
Final Dividend: ₹6.30 per shareDividend Payout vs TTM EPS: ~19.9%டிவிடெண்ட் ஈல்ட்: ~0.73%ரெக்கார்ட் தேதி: ஜூலை 16, 2026AGM Date: ஜூலை 23, 2026
📅 குறுகிய காலம்The stock may see mild interest leading up to the July 16 record date as investors seek to qualify for the dividend payout.
📈 நீண்ட காலம்Limited structural impact from this routine filing, though the appointment of a new Independent Director supports long-term governance.
👀 கவனிக்க வேண்டியவை
Investors should ensure their bank details are updated with depositories by the July 16 record date to receive the dividend, and monitor the AGM for management commentary on the new injectable facility's progress.
ICRA Upgrades Short-Term Rating to [ICRA]A1+; Reaffirms Long-Term [ICRA]A+ (Stable)
ICRA Limited has upgraded Windlas Biotech's short-term credit rating for its working capital facilities to [ICRA]A1+ from [ICRA]A+. The long-term rating for the same facilities, totaling Rs 84.90 crore, has been reaffirmed at [ICRA]A+ with a Stable outlook. This rating action covers facilities across HSBC, HDFC Bank, and IndusInd Bank. Given the company's very low debt-to-equity ratio of 0.06, this upgrade further solidifies its strong credit profile and liquidity position.
உச்சம் நம்பிக்கை
என்ன மாறியதுICRA has upgraded the company's short-term credit rating while maintaining the long-term rating at A+ (Stable).
ஏன் இது முக்கியம்A higher credit rating typically allows a company to negotiate better interest rates with lenders and reflects a robust liquidity position, which is crucial for a CDMO player managing working capital for large clients.
Total Rated Facilities: Rs 84.90 கோடிRated Facilities vs TTM Revenue: ~9.4%Current Debt-to-Equity: 0.06New Short-term Rating: [ICRA]A1+Long-term Rating: [ICRA]A+ (Stable)
📅 குறுகிய காலம்The news is fundamentally positive and confirms financial stability, though it is unlikely to cause a significant short-term price movement given the company's already low debt levels.
📈 நீண்ட காலம்The upgrade supports the company's long-term growth strategy in the injectables and trade generics segments by ensuring access to efficient capital markets and banking facilities.
⚠ அபாய எச்சரிக்கைகள்
High client concentration in the CDMO segment
Potential elongation of the debtor cycle impacting working capital
👀 கவனிக்க வேண்டியவை
Investors should monitor if this credit upgrade translates into lower interest rates on working capital borrowings, which would marginally benefit the OPM (currently 11.6%) as the company scales its new injectables facility.
Windlas Biotech FY26 Revenue Hits Record ₹904 Cr, Up 19%; Proposes ₹6.3 Dividend
Windlas Biotech Limited reported a strong financial performance for FY26, with annual revenue crossing the ₹900 crore milestone for the first time. The company achieved its highest post-listing EPS of ₹31.60 while maintaining capital efficiency with ROCE and ROE consistently above 25%. Growth was primarily driven by the CDMO vertical (up 20%) and the Export vertical (up 40%), supported by a robust net liquidity position of ₹251 crores.
முக்கிய அம்சங்கள்
Annual revenue grew 19% YoY to ₹904 crores, marking 13 consecutive quarters of record revenue.Adjusted EBITDA stood at ₹121 crores (13.4% margin) and PAT at ₹83 crores (9.2% margin) for FY26.Generated ₹105 crores in net operating cash flow and completed a ₹47 crore buyback without promoter participation.Plant 6 has achieved mechanical completion with commercialization expected in H1 FY27.Board proposed a final dividend of ₹6.3 per share, totaling ₹13 crores for the fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the upcoming commercialization of Plant 6 and the scaling of the injectable and export segments, which are expected to drive future growth. The company's strong cash position and high return ratios (25%+) indicate a healthy balance sheet and efficient capital allocation.
Windlas Biotech Reports Record FY26 Revenue of ₹904 Cr, Adjusted PAT Up 31% YoY
Windlas Biotech achieved its 13th consecutive quarter of record revenue, closing FY26 with a total income of ₹904 crore, representing a 19% YoY growth. The company's core CDMO vertical grew by 20% to ₹664 crore, while the export segment surged by 40% to ₹46 crore. Profitability improved significantly with adjusted PAT rising 31% to ₹83 crore and maintaining high return ratios with an ROE of 29% and ROCE of 32%. The company remains net debt-free with a strong liquidity position of ₹251 crore and has proposed a dividend of ₹6.30 per share.
முக்கிய அம்சங்கள்
FY26 Revenue grew 19% YoY to ₹904 Cr; Q4 revenue up 18% YoY to ₹238 CrAdjusted PAT for FY26 increased 31% YoY to ₹83 Cr with an EPS of ₹31.60CDMO vertical, the largest contributor (73%), grew 20% YoY to ₹664 Cr in FY26Strong balance sheet with ₹251 Cr net liquidity and ₹105 Cr cash generated from operationsPlant-6 achieved mechanical completion with commercialization on track for H1 FY27
👀 கவனிக்க வேண்டியவை
Investors should take note of the company's consistent double-digit growth and superior return ratios (ROCE 32%) in the CDMO space. The upcoming commercialization of Plant-6 and expansion into injectables serve as key catalysts for sustained growth in FY27.
Windlas Biotech FY26 Revenue Hits Record ₹904 Cr, Up 19%; Proposes ₹6.30 Dividend
Windlas Biotech reported a strong FY26 with record revenues of ₹904 crore, driven by 20% growth in its core CDMO segment. Adjusted PAT (excluding non-cash ESOP charges) grew significantly by 31% to ₹83 crore, reflecting improved operational efficiency and a 13.4% adjusted EBITDA margin. The company remains net debt-free with a strong liquidity position of ₹251 crore and has proposed a dividend of ₹6.30 per share. Additionally, the completion of a ₹47 crore buyback and the upcoming commercialization of Plant-6 in H1 FY27 signal continued growth momentum.
முக்கிய அம்சங்கள்
Achieved highest-ever annual revenue of ₹904 Cr, marking 13 consecutive quarters of record revenue growth.Adjusted EBITDA (excluding ESOP costs) grew 26% YoY to ₹121 Cr with an improved margin of 13.4%.Core CDMO vertical revenue increased by 20% to ₹664 Cr, while the Export segment grew by 40% to ₹46 Cr.Maintained robust capital efficiency with an ROE of 29% and ROCE of 32% for FY26.Plant-6 mechanical completion achieved; commercialization on track for H1 FY27 to drive future capacity.
👀 கவனிக்க வேண்டியவை
Investors should take note of the company's strong cash flow generation and high return ratios which support the proposed dividend and recent buyback. The upcoming operationalization of Plant-6 and growth in the high-margin Export segment are key catalysts for future valuation re-rating.
Windlas Biotech has approved its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The Board of Directors recommended a final dividend of Rs. 6.30 per equity share, which is 126% of the face value of Rs. 5. The statutory auditors issued an unmodified opinion on the financial statements, indicating no major accounting discrepancies. The company's US subsidiary, Windlas Inc, contributed a small net profit of Rs. 0.21 million for the full year.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs. 6.30 per equity share (126% of face value)Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026Statutory auditors J C Bhalla & Co issued an unmodified audit report for the periodUS subsidiary Windlas Inc reported a total annual net profit of Rs. 0.21 millionDividend payout is subject to approval by shareholders at the upcoming Annual General Meeting
👀 கவனிக்க வேண்டியவை
Investors should view the dividend recommendation as a positive sign of cash flow stability. It is advised to review the detailed profit and loss statement for year-on-year growth trends once the full tables are released.
Windlas Biotech Completes Buyback of 4.7 Lakh Shares at ₹1,000 Per Share
Windlas Biotech has successfully concluded its share buyback program, extinguishing 4,70,000 equity shares at a price of ₹1,000 per share. The buyback was conducted via the tender offer route between April 30 and May 07, 2026. This corporate action has reduced the total paid-up equity shares from 2,11,06,229 to 2,06,36,229. As a result of the share count reduction, the promoter group's shareholding has increased from 61.90% to 63.31%.
முக்கிய அம்சங்கள்
Extinguished 4,70,000 fully paid-up equity shares of face value ₹5 eachBuyback price executed at ₹1,000 per share via the tender offer routeTotal paid-up equity capital reduced from ₹10.55 crore to ₹10.32 crorePromoter and promoter group stake increased from 61.90% to 63.31%The share extinguishment was completed and confirmed by NSDL on May 16, 2026
👀 கவனிக்க வேண்டியவை
The reduction in the total share base is expected to be EPS-accretive for the remaining shareholders. Investors should note the increase in promoter skin-in-the-game as a positive signal regarding the company's long-term value.
Windlas Biotech to Buyback 4.7 Lakh Shares at ₹1,000/Share via Tender Offer
Windlas Biotech has issued a Letter of Offer for the buyback of 4,70,000 equity shares at a price of ₹1,000 per share, totaling ₹47 crore. This represents 2.23% of the company's total equity and 9.80% of its paid-up capital and free reserves as of March 2025. The buyback is being conducted through the tender offer route for shareholders holding shares as of the record date, April 24, 2026. The tendering window is scheduled to open on April 30, 2026, and close on May 07, 2026.
முக்கிய அம்சங்கள்
Buyback of 4,70,000 shares at a fixed price of ₹1,000 per share via tender routeTotal buyback size is ₹47 crore, representing 9.80% of total paid-up capital and free reservesEntitlement ratio is approximately 1 equity share for every 18 shares held as of the record dateBuyback window opens on April 30, 2026, and closes on May 07, 2026The offer covers 2.23% of the total existing paid-up equity share capital of the company
👀 கவனிக்க வேண்டியவை
Eligible shareholders as of the April 24 record date should consider tendering their shares to capitalize on the ₹1,000 buyback price. Ensure that tender forms are submitted through brokers before the May 7 deadline.
Windlas Biotech Approves ₹47 Cr Buyback at ₹1,000/Share; Record Date April 24, 2026
Windlas Biotech's Board has approved a buyback of up to 4,70,000 equity shares at a price of ₹1,000 per share, representing 2.23% of the total paid-up capital. The total buyback size is capped at ₹47 crore, which constitutes 9.80% of the company's aggregate paid-up capital and free reserves. The buyback will be executed through the tender offer route, and the record date for eligibility is fixed as April 24, 2026. Notably, the promoters and promoter group have decided not to participate in this buyback, which likely increases the acceptance ratio for public shareholders.
முக்கிய அம்சங்கள்
Buyback price of ₹1,000 per share is likely at a significant premium to the current market price.Total buyback size of ₹47 crore represents 9.80% of the company's total net worth as of March 31, 2025.Record date for determining eligible shareholders is set for April 24, 2026.Promoters holding 61.90% of the company will not participate, enhancing the potential acceptance ratio for retail investors.15% of the buyback (70,500 shares) is reserved for small shareholders as per SEBI regulations.
👀 கவனிக்க வேண்டியவை
Investors looking to benefit from the buyback premium should ensure they hold the shares in their demat account by the record date of April 24, 2026. The non-participation of promoters makes this an attractive opportunity for retail shareholders due to a potentially higher acceptance ratio.
Windlas Biotech Shareholders Approve Re-appointment of 3 Directors with 99.99% Majority
Windlas Biotech Limited has announced the results of its postal ballot, where shareholders overwhelmingly approved the re-appointment of three key board members. Mr. Ashok Kumar Windlass was re-appointed as Whole-time Director, while Mr. Vivek Dhariwal and Mr. Gaurav Gulati were re-appointed as Independent Directors. Out of 15,320,885 total valid votes cast, 15,320,883 votes (99.99%) were in favor of the resolutions. This ensures leadership continuity for the company starting May 2026.
முக்கிய அம்சங்கள்
Re-appointment of Ashok Kumar Windlass as Whole-time Director approved with 15,320,883 votes in favor.Independent Directors Vivek Dhariwal and Gaurav Gulati re-appointed effective May 6, 2026.High shareholder participation with 72.69% of total outstanding shares polled.Near-unanimous support from institutional and promoter groups, with only 2 votes cast against the resolutions.
👀 கவனிக்க வேண்டியவை
The near-unanimous approval indicates strong shareholder confidence in the current leadership and governance. Investors should view this as a positive sign of stability and continuity in the company's strategic direction.
Windlas Biotech Seeks Approval for Director Re-appointments and ₹1.56 Cr Annual Remuneration
Windlas Biotech has initiated a postal ballot to seek shareholder approval for the re-appointment of Mr. Ashok Kumar Windlass as Whole-time Director for a five-year term starting May 3, 2026. The proposal includes a fixed annual remuneration of ₹1.56 crore and requires a special resolution as he is over 75 years of age. Additionally, the company is seeking a second five-year term for Independent Directors Mr. Vivek Dhariwal and Mr. Gaurav Gulati. Shareholders can participate in remote e-voting from February 18 to March 19, 2026.
முக்கிய அம்சங்கள்
Proposed re-appointment of Mr. Ashok Kumar Windlass as WTD for 5 years with ₹1.56 crore annual salary.Special resolution required for Mr. Windlass to continue in office beyond the age of 75 years.Re-appointment of two Independent Directors, Vivek Dhariwal and Gaurav Gulati, for second 5-year terms.Remote e-voting period set for February 18, 2026, to March 19, 2026, with a cut-off date of February 13.Aggregate remuneration of promoter executive directors may exceed SEBI Regulation 17(6)(e) limits but will remain within Section 197 ceilings.
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results to ensure leadership continuity and evaluate if the proposed remuneration aligns with the company's performance. No immediate portfolio changes are necessary based on this routine governance update.
Windlas Biotech Q3 Revenue Up 20% to INR 233 Cr; Plant 6 Completion Set for FY26
Windlas Biotech reported a strong Q3 FY26 with revenue growing 20% YoY to INR 233 crores, marking its 12th consecutive quarter of record revenue. The CDMO vertical led the performance with 23% growth, while the Exports segment surged 36% due to increased penetration in semi-regulated markets. Management confirmed that Plant 6 is on track for mechanical completion by the end of FY26, which will bring the total revenue capacity to approximately INR 1,100 crores. For the first 9 months of FY26, the company achieved an EPS of INR 24.02, representing a 12% YoY increase.
முக்கிய அம்சங்கள்
Q3 FY26 revenue grew 20% YoY to INR 233 Cr, while 9M FY26 revenue rose 19% to INR 666 Cr.9M FY26 EBITDA (excluding ESOP expenses) stood at INR 89 Cr with a margin of 13.3%.Exports vertical grew 36% in Q3 FY26, significantly outperforming domestic volume growth trends.Plant 6 mechanical completion expected by end of FY26 with an estimated capex of INR 50-60 Cr.Total revenue capacity target set at INR 1,000 Cr for oral solids and INR 100 Cr for injectables.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful commissioning and utilization of Plant 6 and the injectable facility as primary growth catalysts. The company's consistent 12-quarter revenue growth streak and expansion in high-margin exports make it a strong candidate for long-term portfolios in the CDMO space.
Windlas Biotech has received a Show Cause Notice from the Food Safety & Drug Administration (Uttarakhand), resulting in the temporary suspension of Codeine-containing cough syrup manufacturing. This specific product line contributed ₹55.21 crore to the company's total revenue in the current financial year as of February 9, 2026. While the suspension is limited to this product category, the company is preparing a detailed response to address the regulatory concerns and resume operations. Investors should monitor the duration of this suspension as it affects a material revenue stream.
முக்கிய அம்சங்கள்
Temporary suspension of Codeine-containing cough syrup manufacturing by Uttarakhand authorities.Affected product line contributed ₹55.21 crore to revenue in the current FY up to Feb 9, 2026.Suspension is limited to Codeine-based products; other manufacturing operations remain unaffected.Company is in the process of filing a detailed response to the Show Cause Notice within stipulated timelines.
👀 கவனிக்க வேண்டியவை
Investors should monitor the duration of the suspension as the affected revenue is significant. Watch for the company's formal response and any further regulatory actions or clearances from the Food Safety & Drug Administration.
Windlas Biotech Re-appoints Founder and Two Independent Directors for 5-Year Terms
Windlas Biotech has approved the re-appointment of its founder, Mr. Ashok Kumar Windlass, as Whole-time Director for a five-year term starting May 2026. The board also re-appointed Chairman Mr. Vivek Dhariwal and Mr. Gaurav Gulati as Independent Directors for their second five-year terms. These moves ensure leadership continuity and maintain a board with deep expertise in pharmaceutical manufacturing and business strategy. The re-appointments are subject to shareholder approval and will extend the current leadership's tenure until 2031.
முக்கிய அம்சங்கள்
Mr. Ashok Kumar Windlass re-appointed as Whole-time Director for a 5-year term from May 3, 2026, to May 2, 2031.Chairman Vivek Dhariwal re-appointed as Independent Director for a second 5-year term starting May 6, 2026.Gaurav Gulati re-appointed as Independent Director for a second 5-year term starting May 6, 2026.The leadership team brings combined experience from major firms like Pfizer, Baxter, and Oyo Hotels.
👀 கவனிக்க வேண்டியவை
Investors should view this as a sign of management stability and continuity, which is beneficial for long-term strategic execution. No immediate action is required as the existing leadership remains in place.
Windlas Biotech Q3FY26: Revenue up 20% to Rs 233 Cr; 12th Consecutive Record Revenue Quarter
Windlas Biotech reported a strong 20% YoY revenue growth in Q3FY26, reaching Rs 233.1 crore, marking its 12th consecutive quarter of record revenue. While reported PAT for the quarter saw a marginal decline of 4% to Rs 14.9 crore due to non-cash ESOP expenses, adjusted PAT grew significantly. The core CDMO vertical, contributing over 70% of revenue, grew by 23% YoY, while the export segment surged by 36%. For the 9-month period, the company maintained healthy momentum with a 19% revenue increase and a 13% rise in reported PAT.
முக்கிய அம்சங்கள்
Revenue from operations grew 20% YoY to Rs 233.1 crore in Q3FY26, driven by the CDMO segment.Adjusted EBITDA (excluding ESOP expenses) for 9MFY26 rose 26% YoY to Rs 89 crore with a 13.3% margin.CDMO revenue increased 23% YoY in Q3FY26, contributing 71.6% to the total revenue mix.Export vertical showed significant traction with 36% YoY growth in Q3FY26, reaching Rs 13.2 crore.Plant-6 is on track for mechanical completion by the end of FY26, signaling future capacity expansion.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong 20% top-line growth and the robust performance of the CDMO segment, looking past the reported PAT dip caused by non-cash ESOP expenses. The consistent revenue records and upcoming capacity at Plant-6 suggest a positive long-term growth trajectory for the company.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
